Darapladib - CAS# 356057-34-6 205728 XPO1 target occupancy measurements confirm

XPO1 target occupancy measurements confirm the KPT-330recommended phase 2 dose

2019 Sep 20

CID16020046 improves inflammation in models of intestinal inflammation and reduces proinflammatory cytokines

Formula: C10H7KN6O

is a potent JNK inhibitor

Darapladib - CAS# 356057-34-6 205728 XPO1 target occupancy measurements confirmDarapladib, also known as SB 480848, is a reversible lipoprotein associated phospholipase A2 (Lp PLA2) inhibitor with IC50 of 0. 25 nM, which is in Phase 3 trials. Recent studies showed that risk of major coronary events not reduced by darapladib therapy. In patients with stable coronary heart disease, darapladib did not significantly reduce the risk of the primary composite end point of cardiovascular death, myocardial infarction, or stroke. Product